The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma.
Christoph Schulz
No relevant relationships to disclose
Frank Kullmann
Honoraria - Sanofi
Volker Kunzmann
No relevant relationships to disclose
Wolfgang Schepp
No relevant relationships to disclose
Michael Geissler
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Heribert Stauder
No relevant relationships to disclose
Axel Wein
No relevant relationships to disclose
Salah-Eddin Al-Batran
Research Funding - Sanofi
Thomas Kubin
No relevant relationships to disclose
Claus Schaefer
No relevant relationships to disclose
Swantje Held
No relevant relationships to disclose
Sebastian Stintzing
Honoraria - Merck Serono
Stefan Hubert Boeck
No relevant relationships to disclose
Michael Haas
Honoraria - Celgene; Roche
Roswitha Forstpointner
No relevant relationships to disclose
Karsten Ridwelski
No relevant relationships to disclose
Volker Heinemann
Honoraria - Sanofi
Research Funding - Sanofi
Other Remuneration - Sanofi